Thenoyltrifluoroacetone
Names | |
---|---|
IUPAC name
4,4,4-trifluoro-1-(2-thienyl)-1,3-butanedione
| |
Other names
2-thenoyltrifluoroacetone
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.005.743 |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C8H5F3O2S | |
Molar mass | 222.18 g mol−1 |
Appearance | fine, slightly yellow crystals |
Melting point | 40 to 44 °C (104 to 111 °F; 313 to 317 K) |
Boiling point | 96 to 98 °C (205 to 208 °F; 369 to 371 K) 8 mmHg |
Hazards | |
Occupational safety and health (OHS/OSH): | |
Main hazards
|
Xi |
Flash point | 12 °C (54 °F; 285 K) (closed cup) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Thenoyltrifluoroacetone, C8H5F3O2S, is a chemical compound used pharmacologically as a chelating agent. It is an inhibitor of cellular respiration by blocking the respiratory chain at complex II.
Perhaps the first report of TTFA as an inhibitor of respiration was by A. L. Tappel in 1960.[2] Tappel had the (erroneous) idea that inhibitors like antimycin and alkyl hydroxyquinoline-N-oxide might work by chelating iron in the hydrophobic milieu of respiratory membrane proteins, so he tested a series of hydrophobic chelating agents. TTFA was a potent inhibitor, but not because of its chelating ability. TTFA binds at the quinone reduction site in Complex II, preventing ubiquinone from binding. The first x-ray structure of Complex II showing how TTFA binds, 1ZP0, was published in 2005 .[3]
References
- ^ Sigma-Aldrich product page
- ^ Tappel (July 1960). "Inhibition of electron transport by antimycin A, alkyl hydroxy naphthoquinones and metal coordination compounds". Biochem. Pharmacol. 3: 289–96. doi:10.1016/0006-2952(60)90094-0. PMID 13836892.
- ^ "Crystal Structure of Mitochondrial Respiratory Membrane Protein Complex II". Cell. 121 (7): 1043–1047. 2005. doi:10.1016/j.cell.2005.05.025. PMID 15989954.